反応式
Cl[C:2]1[N:7]=[CH:6][C:5]([Cl:8])=[CH:4][N:3]=1.[NH2:9][CH2:10][C@H:11]1[C@@H:16]([O:17][CH3:18])[CH2:15][CH2:14][CH2:13][N:12]1[C:19]([C:21]1[N:22]=[C:23]([CH3:33])[S:24][C:25]=1[C:26]1[CH:31]=[CH:30][C:29]([F:32])=[CH:28][CH:27]=1)=[O:20]>>[Cl:8][C:5]1[CH:4]=[N:3][C:2]([NH:9][CH2:10][C@H:11]2[C@@H:16]([O:17][CH3:18])[CH2:15][CH2:14][CH2:13][N:12]2[C:19]([C:21]2[N:22]=[C:23]([CH3:33])[S:24][C:25]=2[C:26]2[CH:27]=[CH:28][C:29]([F:32])=[CH:30][CH:31]=2)=[O:20])=[N:7][CH:6]=1参加物
3
実験手順
The title compound was prepared following the same general protocol as described for Example 16 using 2,5-dichloropyrimidine and rac-cis-(2-(aminomethyl)-3-methoxypiperidin-1-yl)(5-(4-fluorophenyl)-2-methylthiazol-4-yl)methanone. MS (ESI) 476.0 (M+H).
出典と根拠
- ORDレコード
- ord-bd2361047fdf465ba4eb449179b42927
- 出典データセット
- uspto-grants-2016_09
- 特許番号
- US09440982B2
関連ノート
読み込み中…